Law Firms Compete to Lead Medpace Securities Suit Ahead of June 8 Deadline

Overview

• Robbins Geller issued a May 26 notice setting a June 8 deadline for Medpace investors to seek lead-plaintiff status while other firms, including the Schall Law Firm, have also solicited class members with similar windows.
• The suit, filed as Durbin v. Medpace in the Southern District of Ohio, accuses Medpace and certain executives of overstating a Q4 2025 book-to-bill target, downplaying the impact of cancellations, and misrepresenting pre-backlog diversity.
• The complaint highlights Medpace’s Feb. 9, 2026 earnings disclosure showing a 1.04 book-to-bill ratio and says the stock fell about 16% the next trading day, which plaintiffs say was the corrective disclosure that harmed investors.
• Under the PSLRA, an appointed lead plaintiff will select trial counsel and is expected to push the case into document discovery and possible executive testimony if chosen, which could shape any recovery for shareholders.
• Book-to-bill measures new contracts against billed work for contract research organizations, so the allegations target a metric that directly affects revenue outlooks and could influence investor scrutiny of CRO guidance and executive forecasts.